The two-to three-fold increased mortality associated with active acromegaly can be significantly decreased and even normalised with effective treatment to reduce growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels to within normal limits. This article addresses the advances in surgical techniques, new approaches in radiotherapy and the choice of medical treatments that make it possible to achieve biochemical remission and improve signs and symptoms of disease in almost every patient with acromegaly. The literature is reviewed with regard to the relative merits of each treatment method, recent controversies such as the role of radiotherapy and primary octreotide therapy are discussed and a treatment algorithm is proposed to provide a guide to management.
In the absence of radiotherapy, there is no prospect of a patient being able to discontinue medical therapy; therefore, a financial case can be made for the continuing use of radiotherapy because with time patients may be able to stop high-cost medical treatment. That argument aside, as biochemical control can be achieved in almost every patient by a combination of surgery and medical therapy, we suggest the role of conventional radiotherapy in acromegaly is primarily for controlling continuing tumour growth. Stereotactic radiotherapy in its various forms is superseding multifractional radiotherapy and has a role in the treatment algorithm as an alternative to medical therapy in those patients who have a well-defined area of residual disease at least 5mm away from the optic chiasm post-debulking surgery.
Medical Therapy
At some point in their care, the majority of patients with acromegaly will receive medical therapy, with the choice of agent and the timing of initiation being dependent on a number of factors, including tumour size and location, surgical and radiological intervention, patient choice, side effects and funding. Three classes of drug are available -SSAs, dopamine agonists (DAs) and the GH-receptor antagonist -with each having distinct advantages and drawbacks.
Somatostatin Analogues
Somatostatin is a widely distributed, naturally occurring 14 or 28 amino acid peptide that acts via a family of somatostatin receptors (SSTRs), of which there are five subtypes. The adult human pituitary expresses SSTR-1, -2, -3 and -5 subtypes, but the SSTR-2 and to a lesser extent SSTR-5 are the principal receptors found on somatotroph adenomas, and their activation inhibits GH secretion.
The short half-life of somatostatin (two to three minutes) means it is not a practical form of treatment. The SSAs octreotide and lanroetide are synthetic peptides with a longer half-life and greater receptor specificity for SSTR-2 and SSTR-5. SSAs are the first line of medical therapy following non-curative TSS; both octreotide and lanreotide are available as monthly depot formulations and are effective at achieving biochemical control and induce tumour shrinkage in ≤50% of patients (reviewed in reference 9).
It is difficult to judge the true efficacy of SSAs in achieving biochemical control post-surgery because of the varied entry criteria and therapeutic goals used by the plethora of publications that have addressed the topic.
A meta-analysis that suggested that a long-acting repeatable (LAR) octreotide was superior to lanreotide at normalising IGF-I (63 versus 42%) and reducing GH to <2.5ug/l (54 versus 48%) 10 has been criticised, The disappointing results of the only study to randomise patients to either primary medical therapy or surgery raises the question of whether SSAs are more likely to achieve biochemical control after non- 
Dopamine Agonists
DAs, of which cabergoline is the preferred agent, are relatively ineffective in achieving the modern standards of biochemical control for acromegaly, but have the virtues of being relatively inexpensive and oral.
Cabergoline is not licensed for the treatment of acromegaly and systematic dose-finding studies have never been undertaken. The largest retrospective study demonstrated reductions in IGF-I and GH of 30-40%, sufficient to normalise IGF-I and GH in around 30% of patients.
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They are particularly useful in patients with milder disease (serum IGF-I <130% of the upper limit of normal) and those co-secreting prolactin 27, 28 or in combination with SSAs. 
Pegvisomant
The GH-receptor antagonist pegvisomant is licensed in Europe for treatment of acromegaly in patients unresponsive to other forms of treatment. It is a pegylated GH analogue that acts as a competitive receptor antagonist at the GH receptor. As it does not lower serum GH levels, the primary marker of disease activity is serum IGF-I.
Pegvisomant at doses ≤40mg per day can reduce IGF-I to within the reference range in 97% of patients with active, treated acromegaly, 33 indicating that it should be possible with adequate dose titration to achieve a normal serum IGF-I in virtually every patient.
Although generally well-tolerated and effective at correcting the metabolic defects associated with acromegaly, careful monitoring of liver function is required as a significant rise in transaminases can occur, generally within the first month of therapy. The mechanism is poorly understood and idiosyncratic, and histologically has the appearance of drug-induced hepatitis. To date, it has resolved on stopping the drug, and in some cases even without discontinuation of the medication, with no patients having experienced long-term hepatic damage. 34, 35 The nature of action of pegvisomant, in particular the stimulation of increased GH secretion, has resulted in an understandable concern that long-term therapy may be associated with tumour expansion. Reassuringly, the data from several sources suggest that the natural history of the tumours is unaltered by pegvisomant. Some tumours that were growing prior to pegvisomant have continued to expand, but there is no evidence of the antagonist inducing growth.
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If tumour growth is evident following initial surgery, consideration should be given to repeat surgery or conventional radiotherapy. IGF = insulin-like growth factor.
Adapted from Clemmons et al., J Clin Endocrinol Metab, 2003; 88:4759-67. Pegvisomant is indicated for patients unresponsive to SSA, and in that scenario the choice is whether to add it to ongoing SSA or substitute pegvisomant in place of SSA. Van der Lely's group have described the successful addition of weekly pegvisomant to monthly SSA. 37, 38 This is an attractive option as a means of maintaining any tumour shrinkage that has occurred with an SSA. The only reported study to randomise patients unresponsive to SSA to either combination therapy or pegvisomant monotherapy found similar rates of IGF-I normalisation in both groups, with patients on pegvisomant monotherapy requiring on average 5mg per day more than those on combination therapy 39 -the implication being that there is little difference in the price of the two options, which is contrary to previous claims that combination treatment was significantly less expensive. The decision to use monotherapy or combination treatment depends on individual patient circumstances; for example, good tumour shrinkage with SSA would be a reason for combination treatment, while deteriorating glucose tolerance argues for monotherapy.
Novel Treatments
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Optimal Management Regimen
The treatment regimen for acromegaly should be individually tailored based on informed patient choice and the defined biochemical and clinical goals of treatment. Treatment decisions will take into consideration the desire to achieve biochemical control, relieve symptoms and signs, preserve pituitary function and control tumour size (see Figure 2) .
We would advocate that first-line treatment for the great majority of patients remains TSS performed by an experienced surgeon.
Microadenomas should be cured and debulking of macroadenomas will relieve pressure on structures such as the optic chiasm, and will also improve the likelihood of remission with secondary medical therapy.
Controversy remains in terms of the role of primary medical therapy with SSAs, particularly in centres without adequate neurosurgical expertise. We would certainly recommend pre-operative medical therapy in patients with complications such as sleep apnoea or cardiomyopathy. There is a lack of data to show that pre-treatment of macroadenomas improves surgical complications or remission rates, and we feel the currently available data in terms of long-term morbidity and mortality are insufficient to recommend it replace TSS, but it should be an option for patients who are not fit for surgery or under special circumstances.
Conventional radiotherapy should be reserved for patients with continued tumour growth despite surgical and medical therapy.
However, stereotactic radiotherapy may have a specific role in those patients with a well-defined area of residual disease at least 5mm away from the optic chiasm post-debulking surgery.
Despite these interventions, the majority of patients will require medical therapy. SSAs provide the mainstay of medical treatment, with DA being an option in those with mild elevations of IGF-I and co-secreting prolactin. In Europe, pegvisomant is limited to patients who remain uncontrolled on maximum-dose SSA or who are intolerant of SSAs due to side effects. Combination treatments of SSAs and pegvisomant are increasingly being used as there is some evidence of a synergistic effect of the two medications and benefit in those uncontrolled on either drug alone. The management of acromegaly is complex, but with improved surgical and radiotherapy techniques and multiple medical options, biochemical control should be achievable in all patients. As new medications and techniques evolve, the treatment paradigm will almost certainly change, and patients should be followed closely and re-evaluated on a regular basis. n
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